heterozygous familial hypercholesterolaemia
NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study
The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate
NewAmsterdam shares positive phase 3 results for CETP inhibitor obicetrapib in HeFH
Heterozygous familial hypercholesterolaemia affects approximately one in 250 people globally
Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol
Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment
NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement
The agreement will provide the Dutch biotech with additional resources for its cholesterol-lowering drug candidate